Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Gerresheimer with Innovative SensAIR Platform for 1st Drug Delivery Device for Biologics

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

With SensAIR, Gerresheimer presents for the first time a new platform for on-body infusion pumps which can deliver drugs of higher viscosity, such as monoclonal antibodies (mAb), with precise dosing and safely.

The aim is to provide patients with the best possible support in the subcutaneous delivery of large-volume biologics. The ready-to-use SensAIR On-Body Infusor is easy to use and enables patients to start medication in a self-determined manner in familiar surroundings, for example at home.

The SensAIR On-Body Infusor can be adapted to many medications of different viscosities and different requirements. This applies to the size of the medical device as well as to the needle used, variable cartridge sizes and possible connectivity, for example to the patient’s smartphone. Together with Gerresheimer’s One-Stop-Shop quality promise, which includes a solution from the cartridge to the drug delivery device from a single source, SensAIR enables safe and optimized delivery of biologics.

“Everyone benefits from SensAIR: patients, their relatives and also doctors. This device is an innovative medical device which, when worn on the body, delivers up to 20 ml of biologics subcutaneously to the patient,” says Oliver Haferbeck, Head of the Advanced Technology & Innovation Unit at Gerresheimer and CEO of Sensile-Medical AG. He explains that patients gain significantly in quality of life because they can administer their medication themselves at home. The ready-to-use concept ensures that the patient does not have to carry out any lengthy and complicated preparation steps, but can operate the device simply and safely.

More quality of life for the patient

To date, many patients with a wide variety of indications have to endure long and stressful infusions in a hospital setting to treat their condition. How much easier would it be if patients could carry out the treatment at home? SensAIR makes life easier for these patients, as they can care for themselves over a longer period of time and – depending on the indication – only need to visit the doctor or hospital for check-ups.

SensAIR is an innovative product platform for the infusion of large-volume and highly viscous biologics. The technology, function, design and construction of the platform were jointly developed by Gerresheimer specialists and the product is supplied from a single source.

Safety and cost efficiency

The SensAIR Infusor is characterized by a simple and safe concept which can be cost-effectively adapted to different needs, especially patient needs. Gerresheimer thus offers a platform solution which provides a wide range of options with regard to the biologic to be applied; starting with the drug flow rate (0.15-1.00 ml/min), through type (for example glass cartridge) and volume (up to 20ml) of the primary packaging, to connectivity.

With this focus, SensAIR is attractive to the market even with varying quantities of devices per year, as existing developments and processes can be adapted in the shortest possible time. The existing technologies and know-how, which have already proven themselves in the market, are consistently pursued in SensAIR. This is a significant advantage in terms of time-to-market, among other things by quickly enabling clinical trials.

Gerresheimer is therefore both a partner for the SensAIR device and a supplier and manufacturer of the primary packaging, i.e. the cartridge containing the active ingredient. This represents significant added value as a long-term partner and system supplier.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine